by Alexis Guenette  and Valentina Stosor

Received: 12 March 2025;  Published: 04 September 2025;  doi: 10.21926/obm.transplant.2503256

Provided that cell-mediated immunity (CMI) is known to be vital in managing CMV infection post-transplant along with improving methods to predict the development of cytomegalovirus (CMV) following transplant, CMV-specific-cell-mediated immunoassays have been developed, commercially and research based, to be used in conjunction with pre-transplant CMV serological testing and prophylaxis to help tailor an individual care plan post-transplant. In this review, we assess the status of CMV CMI assays, and their potential [...]

by OBM Transplantation Editorial Office

Received: 03 January 2024;  Published: 04 January 2024;  doi: 10.21926/obm.transplant.2401205

The editors of OBM Transplantation would like to express their sincere gratitude to the following reviewers for assessing manuscripts in 2023. We greatly appreciate the contribution of expert reviewers, which is crucial to the journal’s editorial process. We aim to recognize reviewer contributions through several mechanisms, of which the annual publication of reviewer names is one. Reviewers can download a certificate of recognition directly from our submission system. Additionally, reviewers can sign up to t [...]

by Filomena Emanuela Laddaga  , Bruna Daraia  , Pamela Pinto  , Antonio D’amato  , Stella D’oronzo  , Stefano Martinotti  and Francesco Gaudio

Received: 23 January 2025;  Published: 06 June 2025;  doi: 10.21926/obm.transplant.2502250

Off-the-shelf cellular therapies, utilizing allogeneic T cells derived from healthy donors, represent a promising alternative to autologous chimeric antigen receptor T-cell (CAR-T) therapies for the treatment of hematological malignancies such as leukemias and lymphomas. Unlike autologous approaches, which require the patient’s own cell collection, modification, and expansion, off-the-shelf therapies can be prepared in advance, substantially reducing treatment timelines, decreasing costs, and improving global acces [...]

by Filomena Emanuela Laddaga  , Tommasina Perrone  , Pellegrino Musto  , Ilaria Farella  , Stefano Martinotti  and Francesco Gaudio

Received: 22 February 2025;  Published: 18 June 2025;  doi: 10.21926/obm.transplant.2502253

Primary mediastinal large B-cell lymphoma (PMLBCL) is an aggressive B-cell malignancy that may exhibit resistance to standard chemoimmunotherapy. Novel immunotherapeutic strategies, including checkpoint inhibitors and chimeric antigen receptor T-cell (CAR-T) therapy, are being explored in cases that are refractory to treatment. We report the case of a 29-year-old patient with refractory PMLBCL who was treated with pembrolizumab as a bridging therapy followed by axicabtagene ciloleucel (CAR-T) after failing R-CHOP a [...]

by Marcus Taylor  , Zakariya Mouyer  , Eltigani Abdelaal  and Nnamdi Nwaejike

Received: 23 July 2024;  Published: 22 January 2025;  doi: 10.21926/obm.transplant.2501232

The axillary intra-aortic balloon pump (ax-IABP) has been proposed as an alternative to the femoral IABP, particularly for patients with comorbidities rendering them unsuitable for fem-IABP insertion. Patient mobilisation with the ax-IABP in situ is deemed an additional potential benefit. We reviewed our experience with the ax-IABP. A single-centre retrospective review of all adult patients undergoing cardiac surgery (including heart transplantation) in a UK quaternary cardiac surgery centre between 2017 and 2021 w [...]

by Ziyad Alharbi

Received: 27 March 2024;  Published: 13 January 2025;  doi: 10.21926/obm.transplant.2501231

The supraclavicular artery flap presents a promising solution for facial reconstruction challenges since 1997, surpassing limitations of traditional methods like the deltopectoral flap. Its extended pedicle and thin, pliable epidermis offer reliable outcomes with minimal donor site morbidity, making it a preferred choice for head and neck reconstruction. This systematic review evaluates the efficacy of pre-expanded supraclavicular artery flaps based on a comprehensive analysis. In accordance with the Preferred Repo [...]

by Lúcia Bacalhau  and Patrícia Pontífice-Sousa

Received: 19 September 2024;  Published: 06 February 2025;  doi: 10.21926/obm.transplant.2501233

Allogeneic Stem Cells Transplantation (ASCT) and, consequently, the chronicity associated with this life event has a growing prevalence and a significant impact on the life and daily life of each person who experiences it. The growing number of ASCT survivors highlights the need to reflect on the unique challenges they face throughout their recovery. To understand the meaning of the encounter with time in the lived experience of comfort for survivors of ASCT. Qualitative approach using van Manen's phenomenology of [...]

by Lara Jones  , David Ross  , Andrew Doud  , Navchetan Kaur  , Sangeeta Bhorade  and Holly Keyt

Received: 31 March 2025;  Published: 21 July 2025;  doi: 10.21926/obm.transplant.2503254

The demographics of lung transplant (LT) recipients show an evolution towards increased minority racial/ethnic representation, thanks to an increased focus on inclusion in LT access, healthcare and outcomes. Herein we assess potential differences in LT allograft health in a predominantly Hispanic/Latino (HL) vs Non-Latino/White (NLW) cohort during surveillance for acute rejection by analyzing the fraction of donor-derived cell-free DNA (dd-cfDNA%), a plasma biomarker of allograft injury. Of 245 LT recipients, media [...]

by Alisia Chen  and Jeong M. Park

Received: 29 October 2025;  Published: 24 February 2026;  doi: 10.21926/obm.transplant.2601267

Antibody mediated rejection (AMR) is a considerable cause of late allograft failure in solid organ transplantation. Conventional approaches, using plasmapheresis, intravenous immunoglobulin, rituximab, bortezomib, and eculizumab have been unsuccessful in improving graft survival. This review aims to assess emerging therapies for AMR treatment across all organs. Using a PubMed search, literature published up to July 20, 2025 regarding tocilizumab, clazakizumab, carfilzomib, daratumumab, imlifidase, felzartamab, and [...]

by Chawannuch Ruaengsri  , Marc Leon  , Miguel Alvarez-Cortes  , Manuel Quiroz-Flores  and Yasuhiro Shudo

Received: 30 June 2025;  Published: 21 January 2026;  doi: 10.21926/obm.transplant.2601264

To address the pressing shortage of donor lungs, Donation after Circulatory Death (DCD) transplantation has become a vital strategy for expanding the donor pool. Minimizing warm ischemic injury is crucial for optimizing organ viability and function. This review synthesizes current evidence on Normothermic Regional Perfusion (NRP) and Ex-Vivo Lung Perfusion (EVLP) in DCD lung transplantation. Analysis reveals their growing efficacy in minimizing ischemic damage, facilitating organ assessment, and expanding the trans [...]

by Marina Zafranskaya  , Olesya Shatova  , Elizaveta Nazaranka  , Alena Кurlianskaya  , Galina Ivanchik  , Irina Russkih  , Alesia Vialichka  , Marina Kolyadko  , Tatyana Denisevich  , Svetlana Kulinich  and Darya Nizheharodava

Received: 30 June 2025;  Published: 21 October 2025;  doi: 10.21926/obm.transplant.2504259

To date, all large-scale randomized controlled trials for COVID-19 vaccines have excluded solid organ transplant recipients; therefore, the effectiveness and safety of COVID-19 vaccines in preventing coronavirus infection using COVID-19 vaccines in patients with heart transplants have not been sufficiently studied. This paper presents the characteristics of humoral and cellular immunity in heart transplant recipients following vaccination against coronavirus infection. The study group consisted of 40 patients who u [...]

by OBM Transplantation Editorial Office

Received: 02 January 2025;  Published: 02 January 2025;  doi: 10.21926/obm.transplant.2501229

The editors of OBM Transplantation would like to express their sincere gratitude to the following reviewers for assessing manuscripts in 2024. We greatly appreciate the contribution of expert reviewers, which is crucial to the journal’s editorial process. We aim to recognize reviewer contributions through several mechanisms, of which the annual publication of reviewer names is one. Reviewers can download a certificate of recognition directly from our submission system. Additionally, reviewers can sign up to t [...]

by Vikash Chandra Mishra  , Dinesh Chandra  and Vimarsh Raina

Received: 15 July 2025;  Published: 25 November 2025;  doi: 10.21926/obm.transplant.2504260

Though the role of clinical histocompatibility testing is fundamental to successful transplant, systematic risk assessment and mitigation strategies remain underutilised in this domain. This review addresses risk identification, analysis, and control measures across the pre-analytical, analytical, and post-analytical phases of clinical histocompatibility testing, in line with international standards such as ISO 15189:2022. A structured, risk-based quality management system (QMS) is imperative for ensuring accurate [...]

by Chawannuch Ruaengsri  , Miguel Alvarez-Cortes  , Marc Leon  , Manuel Quiroz-Flores  , Masafumi Shibata  and Yasuhiro Shudo

Received: 30 June 2025;  Published: 30 December 2025;  doi: 10.21926/obm.transplant.2504261

Donation after circulatory death (DCD) offers a vital strategy to expand the donor lung pool; however, DCD lungs are uniquely susceptible to warm ischemic injury during procurement. This chapter reviews evidence-based and emerging donor management strategies aimed at mitigating ischemic damage and optimizing the suitability of DCD lungs for transplantation, encompassing hemodynamic and ventilatory optimization, bronchoscopic clearance, targeted pharmacological interventions, and strategies to minimize transfusion r [...]

by Chawannuch Ruaengsri  , Miguel Alvarez-Cortes  , Marc Leon  , Manuel Quiroz-Flores  , Masafumi Shibata  and Yasuhiro Shudo

Received: 30 June 2025;  Published: 22 January 2026;  doi: 10.21926/obm.transplant.2601265

The increasing demand for organ transplantation has necessitated innovative strategies to maximize donor organ utilization, especially in donation after circulatory death (DCD) contexts. This article explores the integration of direct lung recovery with abdominal normothermic regional perfusion (A-NRP) to optimize organ preservation and expand the donor pool. A-NRP effectively mitigates warm ischemic injury, supporting the viability of both abdominal and thoracic organs. Our approach emphasizes meticulous surgical [...]

by Douglas Sobel  and Wanxing Cui

Received: 09 October 2025;  Published: 20 March 2026;  doi: 10.21926/obm.transplant.2601268

Transplanting islets into the subcutaneous (SC) space rather than the portal vein is advantageous because this site is easier and safer to use. However, transplantation of islets directly or within planar devices has been unsuccessful in humans, mainly because of the low oxygen torr in the SC space. Since human islets are very different from mouse islets, the use of human islets in animal experiments to study SC islet transplantation may help to alleviate the roadblocks of this approach in humans. This is the first [...]

by Mohammed H. Moghadasian

Received: 27 January 2026;  Published: 12 February 2026;  doi: 10.21926/obm.transplant.2601266

Dietary guidelines and Nutrient Reference Intakes are important tools for maintaining optimal health in the general population. Similar guidelines have also been developed by specific organ health associations to help their patient populations recover from disorders or prevent/delay clinical events and subsequent complications. However, there are no specific national and international guidelines to provide dietary and nutrient intake recommendations peri-transplantation. The complex nature of transplantation and in [...]

by OBM Transplantation Editorial Office

Received: 03 January 2026;  Published: 04 January 2026;  doi: 10.21926/obm.transplant.2601263

The editors of OBM Transplantation would like to express their sincere gratitude to the following reviewers for assessing manuscripts in 2025. We greatly appreciate the contribution of expert reviewers, which is crucial to the journal's editorial process. We aim to recognize reviewer contributions through several mechanisms, of which the annual publication of reviewer names is one. Reviewers can download a certificate of recognition directly from our submission system. Additionally, reviewers can sign up to the Web [...]

by Douglas O. Sobel  and Keerat Parmar

Received: 31 August 2025;  Published: 14 April 2026;  doi: 10.21926/obm.transplant.2602269

Subcutaneous transplantation of islets into small-pore macroencapsulation devices that prevent immune cell passage can inhibit allorejection in rodents. However, there are no reports of euglycemia in humans using this technology. This report further develops these macroencapsulation devices. We compared the ability of macroencapsulation transplant devices containing transformed mouse islet cells (MIN-6) with varying polymer membranes, pore sizes, and hydrophilicity to inhibit allorejection and maintain glycemic con [...]

by Isrovanigoro  , Lolita  , Adnan  , Metalia Puspitasari  and Zijie Wang

Received: 27 January 2026;  Published: 09 May 2026;  doi: 10.21926/obm.transplant.2602270

Kidney transplantation is the preferred therapy for end-stage kidney disease (ESKD), but long-term success is greatly influenced by the selection and safety of immunosuppressants. Local data on prescribing patterns and the incidence of drug side effects in Indonesia are still limited. Therefore, this study aims to evaluate induction therapy patterns, immunosuppressant maintenance, and the incidence of drug-related side effects among kidney transplant recipients at a tertiary hospital in Yogyakarta, Indonesia. Mater [...]

by Duong Binh Tran  , Sinh The Pham  , Binh Xuan Luong  and Thi Cao

Received: 16 November 2025;  Published: 26 May 2026;  doi: 10.21926/obm.transplant.2602271

Aseptic femoral shaft nonunion represents a biologically compromised state in which impaired osteogenesis, insufficient vascularity, and inadequate mechanical stability prevent healing. Although mechanical revision is essential, achieving union often requires effective autologous bone tissue transplantation and biologic stimulation. This study evaluated a multimodal revision strategy integrating structural and cancellous autografts with mechanical reconstruction to restore both biological viability and stability at [...]